Pranlukast
Code | Size | Price |
---|
TAR-T0694-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0694-25mg | 25mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0694-50mg | 50mg | £128.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0694-100mg | 100mg | £143.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0694-200mg | 200mg | £174.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
CAS:
103177-37-3
Formula:
C27H23N5O4
Molecular Weight:
481.512
Pathway:
Immunology/Inflammation; GPCR/G Protein; NF-κb; ; Apoptosis
Purity:
0.9985
SMILES:
O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1
Target:
Leukotriene Receptor; IL Receptor; TNF; NF-κB; LTR
References
1. Ichiyama T, et al. Clin Exp Allergy,2003, 33(6), 802-807.
2. Liu YC, et al. Br J Pharmacol,1998, 124(3), 563-571.
3. Ishinaga H, et al. Pharmacology,2005, 73(2), 89-96.
4. Yu GL, et al. Brain Res. 2005 Aug 16;1053(1-2):116-25.
5. Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating na?ve Bayesian classification, molecular docking and drug screening approaches[J]. RSC Advances. 2018 Jan 8(10): 5286-5297.